Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2022-09-30 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-09-30 English
FORM 4
Director's Dealing
2022-09-26 English
FORM 4
Director's Dealing
2022-09-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 14, 2022. It announces a press release about data presentation at a medical conference and includes the press release as an exhibit. The document does not contain financial statements or detailed financial data but rather a disclosure of a press release and event information. The length is 3886 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like earnings release or annual report.
2022-09-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 31, 2022. It announces that the company's independent Data Safety Monitoring Board completed a data review for an ongoing clinical trial and recommended continuation and an adaptive statistical analysis plan. The document includes a press release as an exhibit. The content is an announcement of an event and related disclosure, typical of a current report (8-K), which is a regulatory filing. The document is relatively short (4243 characters) and does not contain detailed financial statements or comprehensive analysis. It is not an annual or quarterly report, earnings release, or other detailed financial report. It is primarily a regulatory announcement of a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-08-31 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 24, 2022. It announces a business agreement between BioCardia, Inc. and BlueRock Therapeutics LP regarding delivery of cell therapy product candidates. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. It is a regulatory announcement of a material event rather than a full financial report or earnings release. The document length is 4135 characters, which is relatively short and consistent with a regulatory filing or announcement. The content fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories such as earnings release, capital update, or management report.
2022-08-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.